Pancreatic Cancer Research

ResearcherUniversity of Arizona College of Medicine- PhoenixActive in the last 2 years

Akihisa Kato

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7733-7854; OpenAlex author ID A5005243857. Sources: OpenAlex.

Their work

Papers
11
Trials
0
Grants
0
Labs led
0
Collaborators
23
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: 1 paper · 2018: 2 papers · 2019: none · 2020: 1 paper · 2021: 3 papers · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper

Papers 11

  1. The role of DPYD and the effects of DPYD suppressor luteolin combined with 5-FU in pancreatic cancer. Co-author DOI 10.1002/cam4.70124↗
  2. Concomitant Pancreatic Ductal Adenocarcinoma and Type 1 Autoimmune Pancreatitis: A Potential Issue in the Diagnosis of Carcinoma by Endoscopic Ultrasound-guide… Co-author DOI 10.2169/internalmedicine.0075-22↗
  3. Class III β-Tubulin Expression Is of Value in Selecting nab -Paclitaxel and Gemcitabine as First-Line Therapy in Unresectable Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000002032↗
  4. A potential signaling axis between RON kinase receptor and hypoxia-inducible factor-1 alpha in pancreatic cancer. Co-author DOI 10.1002/mc.23339↗
  5. DPYD, down-regulated by the potentially chemopreventive agent luteolin, interacts with STAT3 in pancreatic cancer. Co-author DOI 10.1093/carcin/bgab017↗
  6. Autotaxin in ascites promotes peritoneal dissemination in pancreatic cancer. Co-author DOI 10.1111/cas.14689↗
  7. Metachronous Pancreatic Ductal Adenocarcinoma with Adjacent Serous Cystadenoma that Was Preoperatively Diagnosed by EUS-FNA: A Case Report and Review of the Li… Co-author DOI 10.2169/internalmedicine.3912-19↗
  8. The absence of class III β-tubulin is predictive of a favorable response to nab-paclitaxel and gemcitabine in patients with unresectable pancreatic ductal aden… Co-author DOI 10.1016/j.humpath.2018.01.009↗
  9. Case of pancreatic metastasis from colon cancer in which cell block using the Trefle® endoscopic scraper enables differential diagnosis from pancreatic cancer. Co-author DOI 10.4251/wjgo.v10.i3.91↗
  10. Maltotriose Conjugation to a Chlorin Derivative Enhances the Antitumor Effects of Photodynamic Therapy in Peritoneal Dissemination of Pancreatic Cancer. Co-author DOI 10.1158/1535-7163.mct-16-0670↗
  11. Impact of TP53 codon 72 and MDM2 SNP 309 polymorphisms in pancreatic ductal adenocarcinoma. Co-author DOI 10.1371/journal.pone.0118829↗

Closest collaborators

The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Satoru Takahashi · 8 shared papers, 2017–2024 · strength 0.89
  2. Itaru Naitoh · 8 shared papers, 2015–2023 · strength 0.73
  3. Michihiro Yoshida · 8 shared papers, 2015–2023 · strength 0.73
  4. Yasuki Hori · 7 shared papers, 2015–2023 · strength 0.66
  5. Yoichi Matsuo · 4 shared papers, 2020–2024 · strength 0.57
  6. Hiromi Kataoka · 5 shared papers, 2017–2023 · strength 0.55
  7. Kenta Kachi · 4 shared papers, 2020–2023 · strength 0.50
  8. Hiroyuki Kato · 3 shared papers, 2018–2024 · strength 0.39
  9. Shingo Inaguma · 2 shared papers, 2021–2024 · strength 0.32
  10. Naruomi Jinno · 3 shared papers, 2018–2021 · strength 0.29
  11. Takashi Joh · 4 shared papers, 2015–2018 · strength 0.24
  12. Makoto Sano · 1 shared paper, 2024 · strength 0.20
  13. Hideaki Ijichi · 1 shared paper, 2024 · strength 0.20
  14. Tadahisa Inoue · 2 shared papers, 2018–2022 · strength 0.19
  15. Kenji Notohara · 1 shared paper, 2023 · strength 0.15
  16. Kenta Saito · 1 shared paper, 2023 · strength 0.15
  17. Sudhakar Ammanamanchi · 1 shared paper, 2021 · strength 0.13
  18. Serina Ng · 1 shared paper, 2021 · strength 0.13
  19. Haiyong Han · 1 shared paper, 2021 · strength 0.13
  20. Sushovan Guha · 1 shared paper, 2021 · strength 0.13
  21. Hiroyuki Kato · 1 shared paper, 2022 · strength 0.12
  22. Shuji Takiguchi · 1 shared paper, 2018 · strength 0.07
  23. Takashi Murakami · 1 shared paper, 2017 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.